Concord Drugs Ltd Q1FY22 net profit at Rs. 68.77 lakhs

Concord Drugs Limited has reported financial results for the period ended June 30, 2021.

Financial Results (Q1 FY 2021-22) - QoQ Comparison

The company has reported total income of Rs.20.24 crores during the period ended June 30, 2021 as compared to Rs.8.36 crores during the period ended March 31, 2021.

The company has posted net profit / (loss) of Rs.0.6877 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.0.33567 crores for the period ended March 31, 2021.

The company has reported EPS of Rs.0.79 for the period ended June 30, 2021 as compared to Rs.0.38 for the period ended March 31, 2021.

Financials	Q1 FY2021-22	Q4 FY20-21	% Change
Total Income	₹ 20.24 crs	₹ 8.36 crs	142.11%
Net Profit	₹ 0.6877 crs	₹ 0.33567 crs	104.87%
EPS	₹ 0.79	₹ 0.38	107.89%

Financial Results (Q1 FY 2021-22) - YoY Comparison

The company has reported total income of Rs.20.24 crores during the period ended June 30, 2021 as compared to Rs.18.22 crores during the period ended June 30, 2020.

The company has posted net profit / (loss) of Rs.0.6877 crores for the period ended June 30, 2021 as against net profit / (loss) of Rs.0.1654 crores for the period ended June 30, 2020.

The company has reported EPS of Rs.0.79 for the period ended June 30, 2021 as compared to Rs.0.19 for the period ended June 30, 2020.

Financials	Q1 FY2021-22	Q1 FY2020-21	% Change
Total Income	₹ 20.24 crs	₹ 18.22 crs	11.09%
Net Profit	₹ 0.6877 crs	₹ 0.1654 crs	315.78%
EPS	₹ 0.79	₹ 0.19	315.79%

Shares of Concord Drugs Limited was last trading in BSE at Rs. 28.3 as compared to the previous close of Rs. 28.5. The total number of shares traded during the day was 5314 in over 59 trades.

The stock hit an intraday high of Rs. 28.9 and intraday low of 27.1. The net turnover during the day was Rs. 148417.

Source : Equity Bulls

Keywords